@article{a26bbb8352ef4fdbb36ccd304d7def98,
title = "The future of NMR-based metabolomics",
abstract = "The two leading analytical approaches to metabolomics are mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy. Although currently overshadowed by MS in terms of numbers of compounds resolved, NMR spectroscopy offers advantages both on its own and coupled with MS. NMR data are highly reproducible and quantitative over a wide dynamic range and are unmatched for determining structures of unknowns. NMR is adept at tracing metabolic pathways and fluxes using isotope labels. Moreover, NMR is non-destructive and can be utilized in vivo. NMR results have a proven track record of translating in vitro findings to in vivo clinical applications.",
author = "Markley, {John L.} and Rafael Br{\"u}schweiler and Edison, {Arthur S.} and Eghbalnia, {Hamid R.} and Robert Powers and Daniel Raftery and Wishart, {David S.}",
note = "Funding Information: The authors thank the Morgridge Institute for Research, Madison WI, for its financial support for the workshop on “NMR-Based Metabolomics”. Research of the authors received support from NIH R01GM109046 and P41GM103399 (to JLM); NIH R01 GM 066041 (to RB); NIH U24 (SECIM) DK097209-01A1 (to ASE and RB); the Georgia Research Alliance (to ASE); NIH P41GM111135 (to HRE); NIH P20 RR-17675 , P30GM103335 , R01 CA163649-01A1 , and R01 AI087668-01A1 (to RP); NIH R01GM085291 and P30CA015704 (to DR); and Genome Canada support (to DSW). ASE gratefully acknowledges Gary Patti for introducing the term “Metabolic Dark Matter”. JLM thanks Jing Fan for useful comments on the manuscript. Publisher Copyright: {\textcopyright} 2016 The Author(s)",
year = "2017",
month = feb,
day = "1",
doi = "10.1016/j.copbio.2016.08.001",
language = "English (US)",
volume = "43",
pages = "34--40",
journal = "Current Opinion in Biotechnology",
issn = "0958-1669",
publisher = "Elsevier Limited",
}